Identify Key Genes of Ferroptosis and reveals its relationship with immune in Gliomas of different grades: Integrative Analysis from Bioinformatics

Abstract Glioma is one of the most prevalent primary brain tumors, categorized into lower-grade glioma (LGG) and high-grade glioma (HGG), with an annual incidence ranging from 3 to 6 per 100,000 individuals. The genesis and progression of glioma entail complex processes that encompass diverse cellular and molecular mechanisms. By examining the transition of glioma from low grade to high grade, we can unravel its pathophysiological mechanisms and establish a foundation for identifying new therapeutic targets and drugs.Ferroptosis plays a pivotal role in gliomas, linked to critical biological processes including cell proliferation, invasion, and drug resistance.Understanding the role of ferroptosis in glioma onset and progression holds promise for identifying novel targets and strategies in glioma therapy.In this study, we conducted a comprehensive bioinformatics analysis with different grades of glioma, leveraging gene expression data from TCGA and GEO databases. Our integration of differentially expressed genes (DEGs) and ferroptosis drivers revealed a selection of genes, notably DPP4, TFRC, and TIMP1, as significant players in glioma-associated ferroptosis regulation. Validation through real-time quantitative polymerase chain reaction (qPCR) and ferroptosis inhibition confirmed their relevance in glioma pathogenesis. Additionally, our systematic evaluation unveiled the prognostic value of these genes in glioma treatment and their potential impact on immune infiltration dynamics. These findings provide critical insights into ferroptosis-related mechanisms in glioma and offer promising avenues for targeted therapeutic interventions.